Promising breakthrough: mRNA vaccine for melanoma brings real hope in the fight against cancer

The mRNA melanoma vaccine holds real promise in the fight against skin cancer. Excitement is evident among patients and researchers as the vaccine moves into phase 3 testing.

A nurse prepares to give Steve Young, one of the study's first patients, his first injection at UCLH in London - Photo Reproduction/Jordan Pettitt/PA

Skin cancer, especially melanoma, represents a significant challenge for contemporary medicine. However, a new light of hope appears on the horizon of medical research: a mRNA vaccine designed to specifically combat melanoma is demonstrating real promise.Hundreds of patients are undergoing clinical trials of the world's first personalized melanoma vaccine, with doctors and experts praising its "revolutionary" potential to provide a permanent cure against cancer.

Melanoma

Melanoma, a form of skin cancer, originates in melanocytes, cells responsible for producing melanin, which determines skin tone. It is more common among adults with white skin and can appear anywhere on the body, whether on the skin or mucous membranes, manifesting as spots, spots or moles. This type of cancer affects approximately 132,000 people each year worldwide, being the main cause of skin cancer.

Currently, surgery is the primary treatment, although in some cases radiotherapy, medications and chemotherapy are also used. However, now experts are experimenting with new vaccines personalized for each patient, which guide the body to seek out and destroy cancer cells, preventing recurrence of the disease.

The Revolutionary Potential of the mRNA Vaccine

Melanoma, a type of skin cancer, is known for its aggressive ability to spread quickly to other parts of the body, making it highly lethal in advanced stages. Although treatments such as surgery, chemotherapy and immunotherapy have improved the outlook for some patients, there is still an urgent need for more effective therapeutic approaches.

A phase 2 study revealed a significant decrease in the risk of cancer recurrence in melanoma patients after administration of the vaccines. Now a final phase 3 is underway, led by University College London Hospitals NHS Foundation Trust (UCLH). Dr. Heather Shaw, national research coordinator, expressed optimism about the potential to cure melanoma through these vaccines, while they are also being evaluated in other types of cancer, such as lung, bladder and kidney.

“This is one of the most exciting things we’ve seen in a long time,” Shaw said. “This is a really improved tool. Being able to sit down and tell your patients that you're offering them something that is effectively like Bray's Fat Duck versus McDonald's – it's that level of cordon bleu that's coming to them... Patients are really excited about them. .”

Personalized neoantigen therapy, known as mRNA-4157 (V940), is an innovative way to fight cancer. Designed to stimulate the immune system, this vaccine targets tumor neoantigens present in the patient, which are markers expressed by tumors. By carrying up to 34 genetic codes for these neoantigens, the vaccine triggers an immune response targeted to each individual's specific cancer mutations.

To make it unique for each patient, a tumor sample is collected during surgery and undergoes DNA sequencing, using artificial intelligence for personalization. The result is an anti-cancer injection tailored to effectively combat the patient's tumor. Shaw stated that the ultimate purpose is to permanently eradicate cancer in patients.

“I think there is real hope that these will be the game-changers in immunotherapy,” she said.

Promising Study Results

The results of Phase 2 demonstrated that patients with high-risk severe melanoma had a significant reduction in the risk of death or cancer recurrence after three years when they received the vaccine in conjunction with Keytruda immunotherapy treatment. Compared to those who received Keytruda alone, the group receiving the combination was almost half as likely (49%) to experience these adverse outcomes. Patients were administered 1 mg of the mRNA vaccine every three weeks for a maximum of nine doses, plus 200 mg of Keytruda every three weeks for a maximum of 18 doses over approximately one year.

The next phase of the study, Phase 3, will be carried out on a global scale and will have a more diverse sample of patients, with the aim of recruiting around 1,100 people. The UK arm of the study aims to recruit at least 60 to 70 patients across eight centers including London, Manchester, Edinburgh and Leeds. One of the first participants in the study at UCLH is Steve Young, 52, from Stevenage in Hertfordshire. "I'm incredibly excited," he said. "This is my best chance to fight cancer."

Future Perspectives and Challenges to Overcome

While the results so far are exciting, there are still challenges to be overcome before the mRNA vaccine for melanoma can become widely available to patients. Human clinical trials will be needed to evaluate the safety and effectiveness of the vaccine on a larger scale. In addition, large-scale production and distribution logistics also need to be considered.